Monte Rosa Therapeutics’ $222.3 Million Initial Public Offering

Latham & Watkins LLP represented the underwriters in the offering.

Monte Rosa Therapeutics, Inc. executed its initial public offering of 11,700,000 shares of common stock at a public offering price of US$19 per share. All of the shares are offered by Monte Rosa. The shares trade on the Nasdaq Global Select Market under the ticker symbol “GLUE.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Monte Rosa, are expected to be approximately US$222.3 million. In addition, Monte Rosa has granted the underwriters a 30-day option to purchase up to an additional 1,755,000 shares of common stock at the initial public offering price.

J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co., and Guggenheim Securities, LLC acted as underwriters for the offering.

Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with New York associates Biagio Marino and Melange Gavin.

Involved fees earner: Nathan Ajiashvili – Latham & Watkins; Melange Gavin – Latham & Watkins; Alison Haggerty – Latham & Watkins; Biagio Anthony Marino – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Cowen and Company; Guggenheim Securities; J.P. Morgan Securities LLC; Piper Sandler;

Author: Martina Bellini